Clinical trial
A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients…
NCT00276510 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00276510 |
|---|---|
| Title | A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints |
| Official title | Efficacy and Tolerance of EGb 761® 120mg Two Times a Day on Dementia of Alzheimer Type's Onset in Patients Suffering From Memory Complaints. A Randomised, Double-blind, Multicentre, Parallel Groups, Placebo Controlled Phase IIIb/IV Study in Elderly Over 70 |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Memory Disorders, Age-Related, Retention Disorders, Cognitive |
| Intervention type | Drug, Other |
| Interventions | EGb 761® (Tanakan®), Placebo |
| Enrollment | 2,878 |
| Start date | Feb 1, 2002 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Jan 13, 2006 |
| Last update posted | Jan 15, 2019 |
| Countries | France |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: